XENIOS AG, the leader in lung and heart assist therapies, unites the novalung, i-cor, and medos websites into www.xenios-ag.com to further advance the Xenios platform.
With the new XENIOS website, the Heilbronn-based medical device company further advances its unique lung and heart assist therapy platform. The corporate website now integrates the websites of the novalung, medos, and i-cor therapy brands.
As the leading provider of a lung and heart assist platform, the focus of the new online presence is on both - therapy and product. Customers and business partners will find tailored information at XENIOS CAMPUS, an online platform for clinical support, therapy information, and training. The integrated XENIOS Academy continues the tradition of the recognized novalung academy, and offers therapy-specific training options both on site at hospitals and in training centers.
Background information:
XENIOS AG is a leading therapy-driven medical device company focussed on lung and heart assist therapies. The novalung respiratory assist and the i-cor and medos cardiac assist therapies run on the unique Xenios platform.
This system addresses patients with isolated lung or heart failure. Our technologies set new standards in the field of pulmonary and cardiac support and support our patients’ mobility and active participation in the healing process.
Visit the new XENIOS AG “digital business card”:
www.xenios-ag.com
With the new XENIOS website, the Heilbronn-based medical device company further advances its unique lung and heart assist therapy platform. The corporate website now integrates the websites of the novalung, medos, and i-cor therapy brands.
As the leading provider of a lung and heart assist platform, the focus of the new online presence is on both - therapy and product. Customers and business partners will find tailored information at XENIOS CAMPUS, an online platform for clinical support, therapy information, and training. The integrated XENIOS Academy continues the tradition of the recognized novalung academy, and offers therapy-specific training options both on site at hospitals and in training centers.
Background information:
XENIOS AG is a leading therapy-driven medical device company focussed on lung and heart assist therapies. The novalung respiratory assist and the i-cor and medos cardiac assist therapies run on the unique Xenios platform.
This system addresses patients with isolated lung or heart failure. Our technologies set new standards in the field of pulmonary and cardiac support and support our patients’ mobility and active participation in the healing process.
Visit the new XENIOS AG “digital business card”:
www.xenios-ag.com
